© 2016 Mouttet et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background Hormone receptor status and HER2 status are of critical interest in determining the prognosis of breast cancer patients. Their status is routinely assessed by immunohistochemistry (IHC). However, it is subject to intra-laboratory and inter-laboratory variability. The aim of our study was to compare the estrogen receptor, progesterone receptor and HER2 status as determined by the MapQuant ™ test to the routine immuno-histochemical tests in early stage invasive breast cancer in a large comprehensive cancer center. Patients and Methods We retrospectively studied 163 invasive early-stage breast carcinoma with standard IHC status. The genomic status was determined using the MapQuant ™ test providing the genomic grade index. Results We found only 4 tumours out of 161 (2.5%) with discrepant IHC and genomic results concerning ER status. The concordance rate between the two methods was 97.5%and the Cohens Kappa coefficient was 0.89. Comparison between the MapQuant ™ PR status and the PR IHC status gave more discrepancies. The concordance rate between the two methods was 91.4%and the Cohens Kappa coefficient was 0.74. The HER2 MapQuant ™ test was classified as « undetermined » in 2 out of 163 cases (1.2%). One HER2 IHC-negative tumour was found positive with a high HER2 MapQuant ™ genomic score. The concordance rate between the two methods was 99.3% and the Cohens Kappa coefficient was 0.86. Conclusion Our results show that the MapQuant ™ assay, based on mRNA expression assay, provides an objective and quantitative assessment of Estrogen receptor, Progesterone receptor and HER2 status in invasive breast cancer.
Mouttet, D., Laé, M., Caly, M., Gentien, D., Carpentier, S., Peyro-Saint-Paul, H., … Reyal, F. (2016). Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuantTM Microarray Based Assay. PLoS ONE, 11(2). https://doi.org/10.1371/journal.pone.0146474